Stockreport

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers [Yahoo! Finance]

Nkarta, Inc.  (NKTX) 
PDF Rheumatoid arthritis cohort to be added to Ntrust-2 Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected to be [Read more]